Company overview
Basic information
Company name
7 north test, MB
Company code
306047668
Registered address
Klaipėda, Dariaus ir Girėno g. 12-31, LT-92255
Registration date
2022-03-21
Company age: 4 y. 6 mo.
Contact information
Edit data
Phone
Email
Not disclosed
(personal)
Website
None
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Small partnership
NACE activity
Other human health activities n.e.c.
Ownership form
Private without foreign capital
MB "7 north test"
Company code: 306047668
Address: Klaipėda, Dariaus ir Girėno g. 12-31, LT-92255
Download a detailed company report
Make confident decisions with all the information about 7 north test, MB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.
Description
This description was generated by artificial intelligence.
7 north test, MB (company code 306047668) is an operational private small partnership registered in 2022. It is classified as a micro-sized national private non-financial company under private ownership, with governance described as CEO only. The company is based in Klaipeda, Klaipedos city municipality, Klaipedos county, at Dariaus ir Gireno g. 12-31. Its core activity is coded as R.86.99.00, Other human health activities n.e.c.
In the latest financial year, 2025, the company generated revenue of EUR 8.7K and net profit of EUR 5.4K, with a profit margin of 61.8%. This was an improvement from 2024, when revenue was EUR 5.7K and the company recorded a small net loss of EUR 525, although it remained below 2023 levels, when revenue reached EUR 35.4K and net profit was EUR 26.2K. At the end of 2025, equity stood at EUR 52.8K, total assets at EUR 55.2K, and liabilities at EUR 2.4K, indicating a strong equity position. Staff information is reported so far in 2026, but no average employee or wage figures are provided in this dataset.
In the latest financial year, 2025, the company generated revenue of EUR 8.7K and net profit of EUR 5.4K, with a profit margin of 61.8%. This was an improvement from 2024, when revenue was EUR 5.7K and the company recorded a small net loss of EUR 525, although it remained below 2023 levels, when revenue reached EUR 35.4K and net profit was EUR 26.2K. At the end of 2025, equity stood at EUR 52.8K, total assets at EUR 55.2K, and liabilities at EUR 2.4K, indicating a strong equity position. Staff information is reported so far in 2026, but no average employee or wage figures are provided in this dataset.